GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Accolade Inc (NAS:ACCD) » Definitions » YoY EBITDA Growth

Accolade (Accolade) YoY EBITDA Growth : 116.79% (As of Feb. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Accolade YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Accolade's YoY EBITDA Growth for the quarter that ended in Feb. 2024 was 116.79%.

Accolade's EBITDA per Share for the three months ended in Feb. 2024 was $0.05.


Accolade YoY EBITDA Growth Historical Data

The historical data trend for Accolade's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accolade YoY EBITDA Growth Chart

Accolade Annual Data
Trend Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
YoY EBITDA Growth
Get a 7-Day Free Trial 10.93 -14.27 -53.39 18.22 43.84

Accolade Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.72 92.04 33.68 33.91 116.79

Accolade YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Accolade's YoY EBITDA Growth for the fiscal year that ended in Feb. 2024 is calculated as:

YoY EBITDA Growth (A: Feb. 2024 )
=(EBITDA per Share (A: Feb. 2024 )-EBITDA per Share (A: Feb. 2023 ))/ | EBITDA per Share (A: Feb. 2023 ) |
=(-0.925--1.647)/ | -1.647 |
=43.84 %

Accolade's YoY EBITDA Growth for the quarter that ended in Feb. 2024 is calculated as:

YoY EBITDA Growth (Q: Feb. 2024 )
=(EBITDA per Share (Q: Feb. 2024 )-EBITDA per Share (Q: Feb. 2023 )) / | EBITDA per Share (Q: Feb. 2023 )) |
=(0.045--0.268)/ | -0.268 |
=116.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accolade YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Accolade's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Accolade (Accolade) Business Description

Traded in Other Exchanges
Address
1201 Third Avenue, Suite 1700, Seattle, WA, USA, 98101
Accolade Inc offers technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. It generates revenue by providing personalized health guidance solutions to members.
Executives
Richard Eskew officer: EVP General Counsel C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Stephen H. Barnes officer: Chief Financial Officer C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Rajeev Singh director, officer: Chief Executive Officer 6222 185TH AVENUE NE, REDMOND WA 98052
Robert N Cavanaugh officer: President 1601 CLOVERFIELD BLVD., SUITE 620, SANTA MONICA CA 90404
Mchugh Colin officer: Chief Accounting Officer C/O ACCOLADE, INC., 660 W. GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Michael W Hilton officer: Chief Product Officer 6222 185TH AVE, REDMOND WA 98052
Peter S Klein director C/O MICROSOFT CORPORATION, ONE MICROSOFT WAY, REDMOND WA 98052-6399
Cindy Kent director 7601 PENN AVENUE SOUTH, RICHFIELD MN 55418
Patricia L Wadors director C/O ALIGN TECHNOLOGY INC, 881 MARTIN AVE, SANTA CLARA CA 95050
Dawn G Lepore director 1425 BROADWAY PMB 41, SEATTLE WA 99122
Jeffrey D Jordan director 2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
Jeffrey S Brodsky director C/O MORGAN STANLEY 1585 BROADWAY, NEW YORK NY 10036
Thomas J Neff director SPENCER STUART & ASSOCIATES, 277 PARK AVE, NEW YORK NY 10172
William H. Frist director 600 MONTGOMERY STREET, SAN FRANCISCO CA 94111

Accolade (Accolade) Headlines

From GuruFocus

Accolade Inc CEO Rajeev Singh Sells 1,456 Shares

By GuruFocus Research 05-27-2023

Accolade Inc CEO Rajeev Singh Sells 1,578 Shares

By GuruFocus Research GuruFocus Editor 05-25-2023

Accolade Inc CFO Stephen Barnes Sells 640 Shares

By GuruFocus Research GuruFocus Editor 05-25-2023

Accolade To Present at Stifel 2023 Cross Sector Insight Conference

By sperokesalga sperokesalga 06-01-2023